Patrick Cudahy, MD, MSc
DownloadHi-Res Photo
Cards
Appointments
Infectious Diseases
Primary
Titles
Affiliated Faculty, Yale Institute for Global Health
About
Titles
Assistant Professor of Medicine (Infectious Diseases)
Affiliated Faculty, Yale Institute for Global HealthBiography
Dr. Cudahy is an assistant professor in infectious diseases with a research interest in HIV and tuberculosis co-infection. He currently conducts research in South Africa focusing on improving treatment outcomes in people co-infected with tuberculosis and HIV by investigating biomarkers of treatment response and analysis of within-host tuberculosis strain diversity. Dr. Cudahy is board certified in Internal Medicine and Infectious Diseases.
Appointments
Infectious Diseases
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- MSc
- The London School of Hygiene & Tropical Medicine, Epidemiology (2023)
- Fellowship
- Yale University (2017)
- Internship and Residency
- Stanford University (2013)
- MD
- Medical College of Wisconsin (2010)
- BA
- University of California at Berkeley, Molecular and Cell Biology (2005)
Research
Overview
Medical Subject Headings (MeSH)
Biomarkers; Epidemiology; Global Health; HIV; Mycobacterium Infections; Mycobacterium kansasii; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant
ORCID
0000-0003-4462-9567
Research at a Glance
Yale Co-Authors
Frequent collaborators of Patrick Cudahy's published research.
Publications Timeline
A big-picture view of Patrick Cudahy's research output by year.
Research Interests
Research topics Patrick Cudahy is interested in exploring.
Ted Cohen, DPH, MD, MPH
Kenneth Gunasekera
Sheela Shenoi, MD, MPH, FIDSA
14Publications
344Citations
Mycobacterium tuberculosis
Tuberculosis, Multidrug-Resistant
Tuberculosis
HIV
Biomarkers
Publications
2023
Urine and sputum tuberculosis tests: defining the trade-offs in endemic HIV and tuberculosis settings
Wilson D, Cudahy P, Drain P. Urine and sputum tuberculosis tests: defining the trade-offs in endemic HIV and tuberculosis settings. The Lancet Global Health 2023, 11: e809-e810. PMID: 37202010, DOI: 10.1016/s2214-109x(23)00215-2.Commentaries, Editorials and LettersAltmetricMeSH Keywords and Concepts
2022
A doctor at a PHC clinic: A ‘must-have’ or ‘nice-to-have’?
Kerry T, Cudahy P, Holst H, Ramsunder A, McGrath N. A doctor at a PHC clinic: A ‘must-have’ or ‘nice-to-have’? South African Medical Journal 2022, 113: 24-30. PMID: 36537544, DOI: 10.7196/samj.2023.v113i1.16700.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsNon-communicable diseasesPHC clinicsClinic doctorsNurse cliniciansMedical conditionsPatient consultationsCommon non-communicable diseasesPrimary healthcare clinicsMedical servicesComplex clinical conditionsMedical doctorsNational Health InsuranceRenal diseaseClinic levelClinical conditionsChild healthClinic teamHealthcare clinicsClinical complexityMedical consultationClinicMental illnessPatientsCommunicable diseasesDoctor consultationsWhole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
Cox H, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A, Mohr-Holland E, Daniels J, Cudahy PGT, Nicol MP, Borrell S, Reinhard M, Doetsch A, Beisel C, Gagneux S, Warren RM, Furin J. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. Journal Of Clinical Microbiology 2022, 60: e02362-21. PMID: 35170980, PMCID: PMC8925891, DOI: 10.1128/jcm.02362-21.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDrug susceptibility testingRifampicin-resistant tuberculosisShort regimenMDR/RR-TB patientsMDR/RR-TBRR-TB patientsRetrospective cohort studyMore effective treatment regimensHigh-burden settingsRoutine drug susceptibility testingTB drug resistanceEffective treatment regimensWhole-genome sequencingTolerable regimensCohort studyRetrospective cohortRR-TBRegimen changeTreatment regimensTreatment recommendationsPatient outcomesTreatment individualizationClinical dataIndividualized treatmentIneffective drugsPhylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, Chitwood MH, Alexandru S, Bivol S, Russi M, Havumaki J, Cudahy P, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Menzies NA, Warren JL, Crudu V, Colijn C, Cohen T. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLOS Medicine 2022, 19: e1003933. PMID: 35192619, PMCID: PMC8903246, DOI: 10.1371/journal.pmed.1003933.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMultidrug-resistant tuberculosisDrug-resistant M. tuberculosisM. tuberculosis strainsPutative transmission clustersM. tuberculosisTransmission clustersMultidrug-resistant M. tuberculosis strainsTuberculosis strainsMultiple M. tuberculosis strainsCulture-positive TB casesLocal transmissionMDR-TB epidemicDrug-susceptible tuberculosisDrug resistance mutationsDrug resistance profilesUrgency of interventionTB casesDemographic dataNew casesTuberculosisInadequate treatmentNatural historyResistance mutationsBeijing lineageMycobacterium tuberculosis
2021
Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study
Cox H, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F, Dippenaar A, Mohr-Holland E, Daniels J, Cudahy PGT, Borrell S, Reinhard M, Doetsch A, Beisel C, Reuter A, Furin J, Gagneux S, Warren RM. Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study. The Lancet Microbe 2021, 2: e584-e593. PMID: 34766068, PMCID: PMC8563432, DOI: 10.1016/s2666-5247(21)00144-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFirst-line tuberculosis treatmentPrevious tuberculosis treatmentRifampicin-resistant tuberculosisRifampicin-monoresistant tuberculosisTuberculosis treatmentHIV positivityCohort studyLarge-scale prospective cohort studyResistance acquisitionPrevious treatmentRetrospective cohort studyProspective cohort studyTuberculosis drug resistancePatient-level dataLogistic regression analysisWhole-genome sequencingMolecular epidemiology studiesProspective databaseMDR tuberculosisRetrospective cohortFemale sexHigh burdenPatientsHIVEpidemiology studiesRifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S, Reinhard M, Doetsch A, Cudahy PGT, Mohr-Holland E, Daniels J, Dippenaar A, Nicol MP, Gagneux S, Warren RM, Cox H. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. Antimicrobial Agents And Chemotherapy 2021, 65: e00364-21. PMID: 34460307, PMCID: PMC8522772, DOI: 10.1128/aac.00364-21.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMultidrug-resistant TBRMR-TBRR-TBPatient-level clinical dataPhenotypic drug susceptibility testingRifampicin-monoresistant tuberculosisRR-TB patientsMultidrug-resistant tuberculosisHIV-positive individualsRifampin-resistant tuberculosisDrug susceptibility testingRifampin monoresistanceHIV infectionMDR isolatesTB drugsRisk factorsClinical dataSusceptibility testingSubset of isolatesTuberculosisDescriptive studyMycobacterium tuberculosisAvailable WGS dataSignificant differencesPatients
2020
Use of the antenatal antiretroviral (ARV) tracking form in maternity case records to improve ARV management
Kerry T, Cudahy P. Use of the antenatal antiretroviral (ARV) tracking form in maternity case records to improve ARV management. South African Medical Journal 2020, 110: 1206-1212. PMID: 33403967, DOI: 10.7196/samj.2020.v110i12.14505.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsMaternity case recordsQuality of careRecords of womenCase recordsAntiretroviral managementBlood testsCorrect bloodTracking formHIV-positive pregnant womenHIV viral loadRetrospective chart reviewHIV-positive womenTime of deliveryUMgungundlovu DistrictTerms of outcomesBooking visitAntenatal clinicChart reviewViral loadPregnant womenDistrict hospitalBlood resultsMaternity casesWomenCareRisk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study
Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases 2020, 20: 789. PMID: 33097000, PMCID: PMC7585300, DOI: 10.1186/s12879-020-05515-4.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsM. tuberculosis infectionRecurrent tuberculosisSuccessful treatmentTuberculosis recurrenceHazard ratioSmear gradeTuberculosis infectionRisk factorsSmear-positive pulmonary tuberculosisCox proportional hazards modelSputum smear gradeRepetitive unit-variable number tandem repeat (MIRU-VNTR) typingHigh-burden settingsRisk of recurrenceProportional hazards modelSuccessful treatment completionRecurrent diseaseCohort studyPulmonary tuberculosisBurden settingsClinical presentationRecurrent episodesInitial episodeNumber tandem repeat typingTreatment completion
2018
Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings
Cudahy PGT, Andrews JR, Bilinski A, Dowdy DW, Mathema B, Menzies NA, Salomon JA, Shrestha S, Cohen T. Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. The Lancet Infectious Diseases 2018, 19: e89-e95. PMID: 30554997, PMCID: PMC6401264, DOI: 10.1016/s1473-3099(18)30443-2.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTuberculosis incidenceLow tuberculosis incidence settingsActive case-finding strategyHigh tuberculosis (TB) incidence countriesCase-finding strategyTuberculosis control strategiesHigh-incidence settingsInfectious causesIncidence settingsIncidence countriesTuberculosis transmissionTreatment outcomesActive screeningOnward transmissionSystematic reviewInfectious individualsInfectious periodTuberculosisIncidenceDeathCauseProximal causeHIVMixed resultsMortalityTrends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogen
Links & Media
News
- July 27, 2022
New Appointments & Promotions Within Department of Internal Medicine
- March 10, 2022
YSPH-led Study Identifies Drug-Resistant Tuberculosis Strains Spreading in Moldova
- January 02, 2022
Meet Yale Internal Medicine: Patrick Cudahy, MD, Instructor (Infectious Diseases)
- September 16, 2019
2019 Department of Internal Medicine Faculty Appointments and Promotions
Related Links